Lisa Ross

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. pmc Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients
    Lisa L Ross
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 26:407-17. 2010
  2. ncbi request reprint Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities
    Lisa Ross
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    HIV Clin Trials 8:1-8. 2007
  3. ncbi request reprint Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations
    Lisa Ross
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    HIV Clin Trials 7:334-8. 2006
  4. ncbi request reprint Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility
    Lisa L Ross
    International Clinical Virology, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    J Acquir Immune Defic Syndr 43:567-70. 2006
  5. ncbi request reprint A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms
    Lisa Ross
    International Clinical Virology, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    AIDS Res Hum Retroviruses 21:933-9. 2005
  6. doi request reprint Short communication: the number of HIV major NRTI mutations correlates directly with other antiretroviral-associated mutations and indirectly with replicative capacity and reduced drug susceptibility
    L Ross
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 24:617-20. 2008
  7. doi request reprint Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)
    Lisa Ross
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 25:665-72. 2009
  8. pmc Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
    L L Ross
    GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    J Antimicrob Chemother 65:307-15. 2010
  9. ncbi request reprint Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance
    Lisa Ross
    Department of International Clinical Virology at GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS 18:1691-6. 2004
  10. ncbi request reprint Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia
    Denise Paulsen
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 18:1011-9. 2002

Collaborators

Detail Information

Publications20

  1. pmc Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients
    Lisa L Ross
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 26:407-17. 2010
    ....
  2. ncbi request reprint Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities
    Lisa Ross
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    HIV Clin Trials 8:1-8. 2007
    ..As treatment strategies and utilization of antiretroviral drugs evolve, patterns of transmitted mutations may shift...
  3. ncbi request reprint Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations
    Lisa Ross
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    HIV Clin Trials 7:334-8. 2006
    ..In recent ritonavir-boosted protease inhibitor (PI) studies, high efficacy rates have been observed, with few PI mutations detected...
  4. ncbi request reprint Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility
    Lisa L Ross
    International Clinical Virology, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    J Acquir Immune Defic Syndr 43:567-70. 2006
    ..Although the long-term clinical significance of these differences is unclear, they may suggest differential efficacy in some patients with prior NRTI experience, especially those with HIV harboring TAMs...
  5. ncbi request reprint A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms
    Lisa Ross
    International Clinical Virology, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    AIDS Res Hum Retroviruses 21:933-9. 2005
    ..In conclusion, results comparing these two phenotypic tests were mostly similar, but comparisons of the predictive resistance algorithms for specific drugs, as well as to specific phenotypic assays, were more inconsistent...
  6. doi request reprint Short communication: the number of HIV major NRTI mutations correlates directly with other antiretroviral-associated mutations and indirectly with replicative capacity and reduced drug susceptibility
    L Ross
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 24:617-20. 2008
    ..9% for samples with seven to eight NRTI-DRMs. The relatively high percent of samples with NNRTI-DRM but without NRTI-DRMs may result from selection following virologic failure, and/or transmission of virus uniquely resistant to NNRTI...
  7. doi request reprint Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)
    Lisa Ross
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 25:665-72. 2009
    ..These data suggest that TAMs selection is a preferred resistance route of this combination, with zidovudine modulating the resistance pathway against selection for K65R...
  8. pmc Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
    L L Ross
    GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    J Antimicrob Chemother 65:307-15. 2010
    ....
  9. ncbi request reprint Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance
    Lisa Ross
    Department of International Clinical Virology at GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS 18:1691-6. 2004
    ....
  10. ncbi request reprint Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia
    Denise Paulsen
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 18:1011-9. 2002
    ..009), NFV (p = 0.003), and IDV (p = 0.021) but not with prior SQV (p = 0.103). These results suggest that APV and LPV have different cross-resistance mutation patterns that may help determine choice of PI therapy after therapy failure...
  11. ncbi request reprint Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort
    Lisa Ross
    Department of International Clinical Virology, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 21:696-701. 2005
    ..For those where discordance among algorithms existed, further improvement will likely occur as drug resistance pathways for the more recently approved PIs are elucidated...
  12. ncbi request reprint Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects
    Denise Paulsen
    Department of International Clinical Virology, GlaxoSmithKline Inc, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    J Antimicrob Chemother 52:319-23. 2003
  13. ncbi request reprint Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1
    E Randall Lanier
    GlaxoSmithKline, Research Triangle Park, NC 27705, USA
    J Acquir Immune Defic Syndr 39:519-22. 2005
    ..Antagonistic interactions were not detected for any combination. If the systems examined accurately reflect the in vivo situation, antagonism does not substantially contribute to the poor efficacy of this triple combination...
  14. doi request reprint Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1
    Mark R Underwood
    GlaxoSmithKline, Inc, Research Triangle Park, North Carolina 27709 3398, USA
    J Infect Dis 199:84-8. 2009
    ..These findings underscore the limitations of stand-alone phenotypic susceptibility measures and emphasize the importance of complementary and/or more sensitive techniques...
  15. ncbi request reprint Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations
    Ricky Hsu
    Saint Vincent s Medical Center, New York, NY, USA
    Antivir Ther 13:735-7. 2008
    ..Although limited by the single-case nature, the data support a hypothesis that there is no HIV viral RNA or CD4+ T-cell count benefit of taking tenofovir for experienced patients with genotypic evidence of K65R/M184V...
  16. ncbi request reprint A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine
    Lisa L Ross
    AIDS 20:787-9. 2006
  17. ncbi request reprint Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors
    Janet A Englund
    University of Chicago, Pritzker School of Medicine, Chicago, IL, USA
    Pediatr Infect Dis J 23:15-22. 2004
    ..We evaluated the development of antiretroviral genotypic resistance and clinical outcome in a subgroup of children involved in a prospective antiretroviral therapy trial (Pediatric AIDS Clinical Trials Group Protocol 152)...
  18. ncbi request reprint Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: effect of stavudine exposure and antiretroviral experience
    Anthony Scarsella
    Pacific Oaks Medical Center, Beverly Hills, California 90211, USA
    Adv Ther 19:1-8. 2002
    ..Because peripheral neuropathy was observed with such high frequency, vigilance for signs and symptoms of this condition appears warranted if stavudine-containing regimens are to be continued...
  19. ncbi request reprint Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine
    Catherine L Cherry
    Burnet Institute, Melbourne, Victoria, Australia
    J Acquir Immune Defic Syndr 38:263-7. 2005
    ..We assessed the degree and reversibility of adipocyte apoptosis in patients with lipoatrophy before and 48 weeks after substituting abacavir or zidovudine for stavudine...
  20. ncbi request reprint Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine
    Grace A McComsey
    Rainbow Babies and Children s Hospital bCase School of Medicine Center for AIDS Research, Cleveland, Ohio, USA
    AIDS 19:15-23. 2005
    ..As apoptosis and dysfunction of electron transport chain (ETC) activities may underlie mitochondrial toxicity, these parameters were also evaluated...